BioSpace News Archive

The leadership shuffle comes as BMS is facing one of the steepest patent cliffs in biopharma, with exclusivity of three of its top drugs lapsing this decade.

The French pharma drops another BTK inhibitor program from Principia and an anti-TNFa from Ablynx.

While MBAs can reflect positively on job applicants, work experience can often be more valuable, depending on the area.

To be self-employed in the life sciences, you must have a strong network and background and experience in a relevant area.

The joint venture between Walgreens and Prothena to accelerate the approval of an Alzheimer’s treatment is the latest in biotech and retail chain alliances.

Vowst, the first-ever oral fecal microbiome-based therapeutic, is indicated for preventing C. diff recurrence in adults following antibacterial treatment.

Merck and AstraZeneca are seeking broad approval for Lynparza in mCRPC regardless of BRCA status.

For people with, or at risk for, SOD1-ALS, the FDA’s approval of Qalsody is an important step toward advancing gene-specific research for this uniformly fatal disease.

Longitudinal studies that track patients’ experiences can inform and accelerate the drug approval process for rare diseases.

Avacta Group plc announces that the first patient has been dosed in the US under its Investigational New Drug (IND) Application in Avacta’s phase 1 multi-centre trial evaluating the safety and tolerability of AVA6000, a novel tumour targeted form of doxorubicin and Avacta’s first therapeutic product based on its proprietary pre|CISION™ technology.